Last reviewed · How we verify
CMF Chemotherapy
CMF is a combination chemotherapy regimen that uses three cytotoxic agents to inhibit cancer cell division and induce apoptosis.
CMF is a combination chemotherapy regimen that uses three cytotoxic agents to inhibit cancer cell division and induce apoptosis. Used for Breast cancer (adjuvant and metastatic settings).
At a glance
| Generic name | CMF Chemotherapy |
|---|---|
| Sponsor | Universitätsklinikum Hamburg-Eppendorf |
| Drug class | Combination chemotherapy regimen |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
CMF (Cyclophosphamide, Methotrexate, and Fluorouracil) is a polychemotherapy regimen where cyclophosphamide acts as an alkylating agent, methotrexate inhibits dihydrofolate reductase to disrupt nucleotide synthesis, and fluorouracil inhibits thymidylate synthase. Together, these agents target rapidly dividing cancer cells through multiple mechanisms of DNA damage and cell cycle disruption.
Approved indications
- Breast cancer (adjuvant and metastatic settings)
Common side effects
- Myelosuppression (neutropenia, anemia, thrombocytopenia)
- Nausea and vomiting
- Mucositis
- Alopecia
- Fatigue
- Diarrhea
- Cardiotoxicity (with cyclophosphamide)
- Secondary malignancy
Key clinical trials
- Combination Chemotherapy With Trastuzumab in Treating Women With Metastatic Breast Cancer (PHASE2)
- Genetic Testing or Clinical Assessment in Determining the Need for Chemotherapy in Women With Breast Cancer That Involves No More Than 3 Lymph Nodes (PHASE3)
- Adjuvant Chemotherapy With Epirubicin, CMF, and Weekly Docetaxel or Weekly Paclitaxel in Patients With Resected High-risk Breast Cancer
- Randomized Study Comparing Pre- and Postoperative vs. Conventional Adjuvant Treatment in Receptor-negative Patients (PHASE3)
- Tamoxifen in Treating Women With High-Risk Breast Cancer (PHASE3)
- National Surgical Adjuvant Study of Breast Cancer(N-SAS BC) 07 [RESPECT] (PHASE3)
- 4 x Epirubicin, Cyclophosphamide, Followed by 4 x Docetaxel Versus 6 x CMF / 6 x CEF (PHASE3)
- Combination Chemotherapy in Treating Patients With Early Stage Breast Cancer That Has Been Removed By Surgery (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CMF Chemotherapy CI brief — competitive landscape report
- CMF Chemotherapy updates RSS · CI watch RSS
- Universitätsklinikum Hamburg-Eppendorf portfolio CI